The study reveals that 10% of patients treated with eli-cel developed hematologic cancer, with an incidence rate of 2.1 per 100 person-years. This finding emphasizes the need for careful monitoring and risk assessment in gene therapy approaches.

A Connecticut court’s $17.1 million award in a stillbirth case emphasizes the need for vigilant monitoring and timely intervention in pregnancies complicated by liver conditions.

In the BLUE-C trial, Cologuard Plus demonstrated a 93.9% sensitivity for colorectal cancer detection, significantly outperforming the 67.3% sensitivity of FIT.

Chlamydial proctitis can present with symptoms mimicking other conditions, making a thorough sexual history and appropriate testing essential for accurate diagnosis and treatment.

N=1 science empowers patients to become “citizen scientists,” experimenting and refining their health choices to find what works best for their own bodies.

The future of medicine is looking increasingly diverse, with female students now outnumbering males and a growing representation of various racial and ethnic groups in medical school classrooms.